Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
RESEARCH TOOLSreports
Aptose Biosciences (APTO) Stock Price & Analysis
1,196 Followers
APTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.06 - $6.91
Previous Close$1.14
Volume64.14K
Average Volume (3M)66.69K
Market Cap
$18.78M
Enterprise Value$10.54M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 06, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.27
Shares Outstanding16,309,393
10 Day Avg. Volume51,753
30 Day Avg. Volume66,686
Standard Deviation0.26
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-6.52
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$9.75Price Target Upside740.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Launches AML Triplet Therapy Study
PremiumPress Releases
Aptose Reports Results for the First Quarter 2024
PremiumCompany Announcements
Aptose Biosciences Unveils Q1 Results and Clinical Update
PremiumCompany Announcements
Aptose Biosciences Announces Vital Update; Not SEC Filed
PremiumCompany Announcements
Aptose Biosciences Enhances Executive Compensation and RolesBulls Say, Bears Say
Bulls Say
Drug Safety And EfficacyTuspetinib is well-tolerated, and may not require dose modifications which are often needed in current regimens due to toxicities.
Strategic FocusManagement is actively engaged in business development conversations, suggesting a strategic focus on potential partnerships with large pharmaceutical companies.
Treatment PotentialSynergistic activity between tuspetinib and venetoclax has been observed, with resistance to tuspetinib increasing sensitivity to venetoclax.
Bears Say
Clinical DevelopmentManagement is pausing the development in r/r AML for better strategic positioning, potentially delaying progress in another important segment.
Regulatory ApprovalAnalyst lowers price target to $6 from $15, reflecting a later FDA and EMA approval expectation of tuspetinib in AML.
Share DilutionRecent share dilution increased the shares outstanding to approximately 13 million, up from 7 million, which could impact shareholder value.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APTO FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $1.06 and its highest was $6.91 in the past 12 months.
What is Aptose Biosciences’s market cap?
Currently, no data Available
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Aug 06, 2024 which is in 67 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on May 14, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$1.097 by $0.367.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -$0.81.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 16,309,393 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -$0.73 in its last earnings report, beating expectations of -$1.097. Following the earnings report the stock price went down -4.065%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at N/A.
---
Aptose Biosciences Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (740.52% Upside)
$9.75 (740.52% Upside)
Hedge Fund Trend
Decreased
By 96.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.90%
12-Months-Change
Fundamentals
Return on Equity
-361.05%
Trailing 12-Months
Asset Growth
-67.47%
Trailing 12-Months
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
APTO Earnings Call
Q1 2024
0:00 / 0:00
---
APTO Stock 12 Month Forecast
Average Price Target
$9.75
▲(740.52% Upside)
Technical Analysis
Best Analysts Covering APTO
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-15.85%
reiterated a buy rating 7 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -15.85% per trade.
---